Recent developments in protein kinase C inhibitors
- 1 January 1997
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 7 (1), 63-68
- https://doi.org/10.1517/13543776.7.1.63
Abstract
The serine/threonine protein kinase isoenzyme family, protein kinase C (PKC), is a group of closely-related enzymes which apparently mediate a range of responses in different cell types. Their involvement in cellular proliferation and differentiation has made inhibitors of these isoenzymes of great interest as potential anticancer agents. This review looks at compounds under investigation by a number of different pharmaceutical companies within the last two years and reports on their effectiveness in models of cell proliferation and multidrug-resistance.Keywords
This publication has 7 references indexed in Scilit:
- Potent and selective PKC inhibitory 5-membered ring analogs of balanol with replacement of the carboxamide moietyBioorganic & Medicinal Chemistry Letters, 1996
- Staurosporine‐related compounds, K252a and UCN‐01, inhibit both cPKC and nPKCFEBS Letters, 1993
- Balanol: a novel and potent inhibitor of protein kinase C from the fungus Verticillium balanoidesJournal of the American Chemical Society, 1993
- Therapeutic potential of protein kinase C inhibitorsInflammation Research, 1993
- Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase CCancer Chemotherapy and Pharmacology, 1993
- Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation.Proceedings of the National Academy of Sciences, 1992
- Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C.JCI Insight, 1991